Published in Law and Health Weekly, April 7th, 2007
A portion of the proceeds from the third closing will be utilized to complete data analysis required for reporting top-line efficacy results from the Company's twin pivotal Phase III Clinical Trials for its anti-allergy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.